Key result
Replication competent and replication-defective viral vectors offer promising approaches for developing next-generation prophylactics and therapeutics for immune-related diseases and cancer.
Why the study?
Viruses naturally express genes efficiently in host cells, offering potential as gene delivery vectors for gene and immunotherapies across immune-related, autoimmune, and degenerative disorders.
Viral gene delivery vectors offer potential as next-generation prophylactics and therapeutics for immune-related diseases, cancer, and genetic disorders.
Should not yet change practice; leaves open whether viral vectors will prove safe and superior in prospective trials.
Viruses have evolved to efficiently express their genes in host cells, which makes them ideally suited as gene delivery vectors for gene and immunotherapies. Replication competent (RC) viral vectors encoding foreign or self-proteins induce strong T-cell responses that can be used for the development of effective cancer treatments. Replication-defective (RD) viral vectors encoding self-proteins are non-immunogenic when introduced in a host naïve for the cognate virus. RD viral vectors can be used to develop gene replacement therapies for genetic disorders and tolerization therapies for autoimmune diseases and allergies. Degenerative/inflammatory diseases are associated with chronic inflammation and immune responses that damage the tissues involved. These diseases therefore strongly resemble autoimmune diseases. This review deals with the use of RC and RD viral vectors for unraveling the pathogenesis of immune-related diseases and their application to the development of the next generation prophylactics and therapeutics for todays' major diseases.
No takes yet. Share an insight, caveat, or question.
Haan et al. (2020) conducted a review in Immune-related diseases, cancer, genetic disorders, autoimmune diseases, and allergies. Viral gene delivery vectors (replication competent and replication-defective) was evaluated. Replication competent and replication-defective viral vectors offer promising approaches for developing next-generation prophylactics and therapeutics for immune-related diseases and cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: